NL-1

生物活性靶点体外研究体内研究 NL-1 试剂级价格

NL-1

CAS号:188532-26-5
英文名:NL 1
中文名:NL-1
CBNumber:CB65417106
分子式:C18H25NO3S
分子量:335.46
MOL File:188532-26-5.mol

NL-1化学性质

沸点 :446.5±40.0 °C(Predicted)
密度 :1.167±0.06 g/cm3(Predicted)
储存条件 :Sealed in dry,Store in freezer, under -20°C
溶解度 :DMSO: 250 mg/mL (745.25 mM)
酸度系数(pKa) :6.34±0.50(Predicted)
形态 :Solid
颜色 :White to off-white

NL-1性质、用途与生产工艺

生物活性 NL-1 是一种具有抗白血病作用的 mitoNEET 抑制剂。NL-1 抑制 REH 和 REH/Ara-C 细胞生长，IC50 分别为 47.35 µM 和 56.26 µM。NL-1 介导的白血病细胞死亡需要激活自噬途径。
靶点

MitoNEET

体外研究

NL-1 (10-100 μM; 72 hours; REH, REH/Ara-C and ALL cell lines) treatment reduces the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. NL-1 inhibits SUPB15, NALM6 with IC ₅₀ s of 29.48 µM, 94.26 µM, respectively. TOM1, BV173, NALM1 and JM1 all have similar IC ₅₀ values of around 60 µM for NL-1.
NL-1 (60 μM; 6 hours; REH, REH/Ara-C cell lines) treatment mediates autophagy, and inhibition of autophagy partially decreased NL-1-induced tumor cell death.
NL-1 pretreatment inhibits the chemotactic ability of both REH and REH/Ara-C cells to migrate towards multiple chemoattractants. The cells treated with NL1 shows a dose-dependent decrease in chemotaxis both in the REH and the REH/AraC cells.

Cell Proliferation Assay

Cell Line:	REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines
Concentration:	10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 100 μM
Incubation Time:	72 hours
Result:	Reduced the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner.

Cell Autophagy Assay

Cell Line:	REH, REH/Ara-C cell lines
Concentration:	60 μM
Incubation Time:	6 hours
Result:	Induced cell autophagy.

体内研究

NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model.

Animal Model:	10 female NOD.Cg- Prkdc ^scid Il2rg ^tm1Wjl /SzJ (NSG) mice (6-8 month old) injected with TOM-1 ALL cells
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; daily; for 5 days
Result:	Showed antileukemic activity in an in vivo mouse ALL model.